Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Reproductive Toxicology
- Vol. 95, 45-50
Abstract
No abstract availableKeywords
Funding Information
- Sanofi Genzyme
This publication has 16 references indexed in Scilit:
- Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing dataSeminars in Arthritis and Rheumatism, 2016
- Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and PsoriasisDrug Safety, 2016
- Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in JapanModern Rheumatology, 2016
- Pregnancy outcomes following exposure to abatacept during pregnancySeminars in Arthritis and Rheumatism, 2015
- Pregnancy Outcome After Methotrexate Treatment for Rheumatic Disease Prior to or During Early Pregnancy: A Prospective Multicenter Cohort StudyArthritis & Rheumatology, 2014
- Pregnancy outcome in women exposed to leflunomide before or during pregnancyArthritis & Rheumatism, 2012
- Maternal exposure to leflunomide and methotrexate in a patient with adult-onset Still's diseaseRheumatology, 2010
- Birth outcomes in women who have taken leflunomide during pregnancyArthritis & Rheumatism, 2010
- Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in miceReproductive Toxicology, 2007
- Reporting bias in retrospective ascertainment of drug-induced embryopathyThe Lancet, 1999